SteadyMed Therapeutics has named pulmonary hypertension (PH) advocate Carl Hicks Jr. to its newly created position of vice president for PH patient advocacy and community relations. Hicks has been fighting PH for over 20 years. He is recognized as a leader in the PH community through the U.S. and worldwide, advocating…
News
Researchers at Cedars-Sinai Medical Center received a $7.3 million grant from the California Institute for Regenerative Medicine to pursue the development of a new stem cell therapy for pulmonary arterial hypertension (PAH). Working with Capricor Therapeutics, the grant will support a clinical trial to test infusions of…
Although women with pulmonary arterial hypertension (PAH) are advised to avoid pregnancy, increasing numbers opt to tackle the risks to have a child. A recent review discussed the risks, and the best way to manage pregnancy in PAH. The review, “Pregnancy in pulmonary arterial hypertension,” published in the…
Pulmonary arterial hypertension (PAH) patients who carry mutations in a gene called BMPR2 have a very distinctive profile, a new study reports. Due to bronchial arterial remodeling and new vessel formation, these patients are more prone to coughing up blood from the lungs or bronchial tubes (hemoptysis), and to showing increased…
Nitric oxide inhalation can significantly improve oxygen supply in newborn babies with pulmonary hypertension according to a study published in the journal European Review for Medical and Pharmacological Sciences.
Researchers have identified a noninvasive way to predict disease outcomes in patients with pulmonary arterial hypertension (PAH) that uses three-dimensional measures of the right heart ventricle. The method allows physicians to assess the risk of deterioration without exposing patients to repetitive heart catheterization — and may offer a way to…
Chinese scientists have identified a large number of proteins that are differentially expressed in the blood of people with pulmonary arterial hypertension associated with congenital heart disease (CHD-PAH), for the first time.
Sildenafil appears to treat pulmonary hypertension (PH) by reducing the recruitment of bone marrow (BM)-derived progenitor cells, cells now being seen as potential key drivers of lung remodeling and inflammation in diseases that include PH. The study, “Sildenafil attenuates hypoxic pulmonary remodelling by inhibiting bone marrow progenitor cells,” was published in the…
Measures of pulmonary arterial capacitance (PAC) may help to predict the risk of heart problems in patients with pulmonary hypertension caused by left heart disease. But before the method might be applied in the clinic, studies are needed to confirm its usefulness. The study, “Pulmonary Arterial Capacitance Predicts Cardiac Events in…
The specific benefits of balloon pulmonary angioplasty (BPA) on the respiratory function of patients with chronic thromboembolic pulmonary hypertension (CTEPH) depends on what area of the lung, or lung field, the procedure is performed on, according to new research. This finding was published in the article “Effect Of Balloon Pulmonary Angioplasty…
November is Pulmonary Hypertension Awareness Month and, in recognition, SteadyMed has announced the launch of its new website, BePHenomenal.com, dedicated to educating people with pulmonary hypertension (PH) so as to empower them to live the healthiest and most PHenomenal lives possible. The Pulmonary Hypertension Association notes…
Researchers suggest that a protein called ED-A+ Fn (ED-A domain containing fibronectin) could serve as a marker for pulmonary hypertension (PH), aiding in diagnosis and allowing better monitoring of treatment responses. The study, “Lung tissue remodelling in MCT-induced pulmonary hypertension: a proposal for a novel scoring system and…
